- Al-Harbi K et al. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer Adherence 2012; 6: 369-388.
- Rush AJ1, Trivedi MH, Wisniewski et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163(11): 1905‒1917.
- World Health Organisation. Depression and Other Common Mental Health Disorders: Global Health Estimates, 2017. Available from: https://bit.ly/2Gzn8CJ (link is external). Last accessed September 2018.
- World Federation for Mental Health. DEPRESSION: A Global Crisis, 2012. Available from: https://bit.ly/1SX2x6J (link is external). Last accessed September 2018.
- World Health Organisation. Depression Fact Sheet, 2018. Available from http://www.who.int/news-room/fact-sheets/detail/depression (link is external). Last accessed September 2018.
- Diagnostics and statistical manual of mental disorders. Fifth Edition. 2013.
- APA. Practice guidelines for the treatment of patients with major depressive disorder. Third edition, 2010.
- Lepine JP, Briley M. The increasing burden of depression.Neuropsychiatr Dis Treat 2011; 7(Suppl 1): 3-7.
- Ferrari AJ, Charlson FJ, Norman RE et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med 2013;10(11): e1001547.
- Sobocki P, Jönsson B, Angst J et al. Cost of depression in Europe. J Ment Health Policy Econ 2006; 9(2): 87-98.
- Anacker C. New Insight Into the Mechanisms of Fast-Acting Antidepressants: What We Learn From Scopolamine. Biol Psychiatry 2018; 83(1): e5-e7.
- Leuchter AF, Cook IA, Hunter AM et al. A new paradigm for the prediction of antidepressant treatment response. Dialogues Clin Neurosci 2009; 11(4): 435–446.
- Munoz C. recovering usual functioning in depressed patients. Medicographia 2014; 36(4): 501-507.
- Machado-Vieira R, Baumann J, Wheeler-Castillo C et al. The Timing of Antidepressant Effects: A Comparison of Diverse Pharmacological and Somatic Treatments. Pharmaceuticals 2010; 3(1): 19-41.
- Machado-Vieira R, Salvadore G, Luckenbaugh DA et al. Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry 2008; 69(6): 946-958.
- Oluboka OJ, Katzman MA, Habert J et al. Functional Recovery in Major Depressive Disorder: Providing Early Optimal Treatment for the Individual Patient. Int J Neuropsychopharmacol 2017; 21(2): 128-144.
- Gormley N1, O'Leary D, Costello F et al. First admissions for depression: is the 'no-treatment interval' a critical predictor of time to remission?. J Affect Disord 1999; 54(1-2): 49-54.
- Okuda A, Suzuki T, Kishi T et al. Duration of untreated illness and antidepressant fluvoxamine response in major depressive disorder. Psychiatry Clin Neurosci 2010; 64(3): 268-273.
- Bukh JD, Bock C, Vinberg M et al. The effect of prolonged duration of untreated depression on antidepressant treatment outcome. J Affect Disord 2013; 145(1): 42-48.
- Reid I, Cameron I, MacGillivray S et al. Depression: current approaches to assessment and treatment. Prescriber 2014; 25(4): 16-20.
- van Krugten FC, Kaddouri M, Goorden M et al. Indicators of patients with major depressive disorder in need of highly specialized care: A systematic review. PLOS One 2017; 12(2): e0171659.